Saturday 17 October 2026 Export LFCR’s income statement to Excel — free account

Lifecore Biomedical, Inc.

LFCR Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 6.25%, EPS fell 216.7%, free cash flow fell 117.0% and total debt rose 15.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

6.38 0.06 −0.93%

Follow LFCR

Alert me

Market cap: $244.1M
P/E: 0.0×
Fwd P/E: −5.4×
Dividend yield: —
F-score: 3/9
Altman Z: 0.12
Beneish M: −3.15
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 8.80%

Capital & Financial Ratios $m

Market Cap 244.12

Revenue 119.58

Net Income (21.14)

Free Cash Flow (5.06)

Net Debt 167.78

Current Ratio 3.87

Debt/Equity 11.50

P/E ratio 0.00

Fwd P/E (5.39)

P/S ratio 2.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 42.91%

Next Y EPS Growth 40.69%

Next Y revenue growth (6.03%)

Next 5Y EPS Growth 10.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 68.28%

10-year low 10-year high

EV/Sales against its own 10 years 73.84%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	19	8	8	17
Receivables	29	27	29	30
Inventory	41	40	32	25
Other	5	4	7	8
	94	81	86	84

	2023	2024	2025	Q'26
Payables	22	16	8	8
ST’ Debt	1	1	—	—
Other	—	—	—	—
	39	39	30	22

Compound Annual Growth %

	10y	5y	3y
Sales	(13.34%)	(4.24%)	5.02%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(14.23%)	(27.14%)	(18.56%)

Revenue $m

	Aug	Nov	Feb	May	Year
’26	31	—	—	—	—
’25	25	33	35	26	129
’24	25	30	36	38	128
’23	24	22	27	31	103
’22	42	43	37	(11)	111
’21	136	131	45	(210)	101
’20	139	143	153	(274)	160

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	2	—	—	—	—
’25	(1)	(6)	(6)	5	0
’24	(8)	1	(8)	9	0
’23	(1)	(2)	(15)	(2)	(17)
’22	1	(5)	(22)	(1)	(23)
’21	17	1	11	6	16
’20	(5)	(9)	(4)	(13)	(17)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	0	—	—	—	—
’25	(4)	(9)	(10)	3	(7)
’24	(13)	(3)	(24)	6	(18)
’23	(4)	(3)	(29)	(9)	(39)
’22	(6)	(10)	(39)	(12)	(51)
’21	17	7	12	(8)	4
’20	(15)	(16)	(24)	(17)	(41)

Fiscal quarters ending in the months shown.

EPS $

	Aug	Nov	Feb	May	Year
’26	—	—	—	—	—
’25	(0.53)	(0.19)	(0.40)	(0.06)	(1.11)
’24	(0.35)	0.39	0.43	(0.20)	0.33
’23	(0.37)	(0.43)	(1.20)	(1.19)	(3.32)
’22	(0.32)	(1.30)	(0.44)	(1.24)	(3.96)
’21	(0.38)	(0.45)	(0.19)	(0.10)	(1.10)
’20	(0.16)	(0.23)	(0.39)	(0.52)	(1.31)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	9.48	11.20	11.45	9.00	7.48	7.65	6.23	1.52	3.68	4.76	Analyst estimates 2026–2028 Powerpack
	High	15.50	14.95	15.60	13.24	11.89	12.88	12.04	11.46	8.90	8.85
People
People	Employees	552	670	710	736	796	905	689	459	524	406
	Revenue/emp, $m	0.86	0.70	0.74	0.76	0.20	0.11	0.16	0.22	0.24	0.32
Income, $m
Income, $m	Revenue	477	470	524	558	160	101	111	103	128	129
	Gross margin, %	14.00	16.86	14.94	14.53	24.61	38.60	35.11	27.10	32.63	31.27
	EBT	(20)	14	16	4	(31)	(30)	(21)	(64)	10	(39)
	EBT margin, %	(4.13)	3.02	3.13	0.65	(19.15)	(29.53)	(18.59)	(61.90)	7.42	(30.01)
	Net income	(11)	11	25	0	(38)	(32)	(117)	(100)	12	(39)
	Depreciation	9	11	12	15	32	20	96	14	8	8
Per share, $
Per share, $	Revenue	17.63	17.22	19.04	19.66	5.49	3.44	3.78	3.45	4.21	3.70
	Earnings	(0.42)	0.39	0.91	0.01	(1.31)	(1.10)	(3.96)	(3.32)	0.39	(1.11)
	Cash flow	0.77	1.09	0.72	0.56	(0.58)	0.56	(0.77)	(0.58)	0.01	(0.01)
	Capex	(1.46)	(0.84)	(1.22)	(1.57)	(0.83)	(0.42)	(0.98)	(0.72)	(0.60)	(0.18)
	Free cash flow	(0.70)	0.25	(0.50)	(1.00)	(1.42)	0.14	(1.74)	(1.30)	(0.60)	(0.19)
	Book value	7.85	8.36	9.17	9.53	7.92	6.92	2.98	1.17	1.77	1.36
	Shares, m	27	27	28	28	29	29	29	30	30	35
Valuation, ×
Valuation, ×	P/E	0.00	35.77	15.62	781.10	0.00	0.00	0.00	0.00	14.75	0.00
	P/S	0.66	0.81	0.74	0.50	1.97	3.38	2.52	2.38	1.39	1.85
	P/B	1.47	1.67	1.54	1.04	1.37	1.68	3.09	0.00	15.73	179.05
	EV/Sales	0.76	0.92	0.87	0.77	3.16	5.29	3.84	3.80	2.49	2.97
	EV/FCF	(11.52)	55.76	(27.38)	(10.16)	(7.01)	19.00	(6.32)	(8.46)	(9.26)	(30.80)
Cash, $m
Cash, $m	Operating cash flow	21	30	20	16	(17)	16	(23)	(17)	0	0
	Capex	(40)	(23)	(33)	(44)	(24)	(12)	(29)	(21)	(18)	(6)
	Free cash flow	(19)	7	(14)	(28)	(41)	4	(51)	(39)	(18)	(7)
Balance, $m
Balance, $m	Working capital	30	30	9	(4)	(7)	46	(60)	55	42	55
	Total debt	61	54	73	149	190	194	148	167	150	152
	Net debt	51	48	70	148	190	193	147	147	141	144
	Shareholders’ equity	212	228	253	270	231	203	88	35	54	47
Returns, %
Returns, %	ROA	(3.38)	3.02	6.51	0.09	(7.20)	(6.19)	(30.02)	(37.70)	4.73	(17.98)
	ROIC	(4.89)	3.32	2.63	0.82	(3.84)	(1.39)	(3.14)	(7.46)	(2.83)	(5.64)
	ROE	(5.38)	4.81	10.33	0.16	(15.24)	(14.89)	(80.32)	(238.21)	339.11	(701.27)

Negative figures in brackets.

All 10 years →

Fiscal years to May 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
CGC Canopy Growth Corporation	$311.2M	— (loss-making)	— (loss-making)	+12.41% (above 0%: growing)	n/m	−117.60% (below 0%: shrinking)	27.40%	(27.24%)	Compare
ANIK Anika Therapeutics Inc.	$276.9M	— (loss-making)	— (loss-making)	+15.56% (above 0%: growing)	n/m	+61.58% (above 0%: growing)	65.15%	9.06%	Compare
ACB Aurora Cannabis Inc.	$265.8M	— (loss-making)	— (loss-making)	−31.15% (below 0%: shrinking)	n/m	−293.56% (below 0%: shrinking)	52.73%	(12.92%)	Compare
BIOA BioAge Labs, Inc.	$245.6M	— (loss-making)	— (loss-making)	+1.62% (above 0%: growing)	n/m	+2.68% (above 0%: growing)	100.00%	(1,196.78%)	Compare
LFCR Lifecore Biomedical, Inc.	$244.1M	— (loss-making)	— (loss-making)	−6.25% (below 0%: shrinking)	n/m	−117.03% (below 0%: shrinking)	35.34%	7.51%
SIGA Siga Technologies Inc.	$229.2M	— (loss-making)	28.7×	−49.45% (below 0%: shrinking)	−66.00% (below 0%: shrinking)	−75.95% (below 0%: shrinking)	57.17%	33.91%	Compare
AKBA Akebia Therapeutics, Inc.	$192.7M	— (loss-making)	— (loss-making)	−21.36% (below 0%: shrinking)	n/m	−88.99% (below 0%: shrinking)	78.78%	(12.88%)	Compare
Median of peers	$271.4M	—	—	+7.02%	—	−61.81%	57.87%	(18.32%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Lifecore Biomedical, Inc. (LFCR) key facts

Lifecore Biomedical, Inc. (LFCR) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LFCR traded at $6.38, a market capitalization of $244.1 million.
Return on equity was −701.3% and debt-to-equity 11.50.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.12 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.